Pershing Square Capital Management clients aren't very concerned about Herbalife's big gain yesterday.» Read More
WASHINGTON, July 24- A U.S. lawmaker will pressure the U.S. Securities and Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.
Allergan fell$. 71 or. 4 percent, to $170.43. Boston Scientific Corp. rose$. 30 or 2.4 percent, to $12.85. Medtronic rose$. 30 or. 5 percent, to $62.71.
Allergan rose $1.04 or. 6 percent, to $172.18. Baxter International Inc. rose$. 55 or. 7 percent, to $76.66. Boston Scientific Corp. rose$. 23 or 1.8 percent, to $12.78.
Microsoft makes design central to its future. Before Ralf Groene helped devise the look and feel of Microsoft's Surface tablet, he designed food— or "food concepts," he says, such as dried noodles that come wrapped around a pair of chopsticks and a fork that squeezes out sauce.
July 21- Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc, said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.
CNBC's Meg Tirrell reports Allergan posted Q2 results that beat on earnings and sales, as the company announced its restructuring plans, which may include an acquisition of its own.
Some of Monday's midday movers:
NEW YORK, July 21- U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and Gaza continue to garner investor focus.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, said on Monday that it would cut 13 percent of its global workforce as part of a restructuring meant to boost profits over the next six years.
CNBC's David Faber reports Allergan is cutting 13 percent of its workforce and Valeant complains to the SEC and Canadian regulators about Allergan statements.
IRVINE, Calif.— Allergan Inc. on Monday reported profit that climbed by 16 percent in its second quarter, and topped analysts' expectations. The Irvine, California- based company said earnings increased to $417.2 million, or $1.37 per share, from $359.9 million, or $1.19 per share, in the same quarter a year ago.
CNBC's David Faber reports activist investor Elliot Management reportedly has taken and more than $1 billion stake in EMC. And Allergan announces plans to cut 1,500 jobs as it continues fighting a takeover from Valeant.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, on Monday announced 1,500 jobs cuts as part of a $475 million restructuring meant to boost profits over the next six years.
CNBC's Jim Cramer shares his thoughts on the feud between Allergan and Valeant, and weighs in on how a slowdown in Europe would likely impact U.S. markets.
Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals. Allergan Inc. has rejected several takeover attempts from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman's Pershing Square Capital Management.
U.S. stock index futures pointed to a lower open on Monday, with investor sentiment subdued due to the ongoing turmoil in Gaza and Ukraine.
Allergan on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.
Some of the names on the move ahead of the open.
Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.